Related Experiment Videos
Pharmacogenetics in Europe: barriers and opportunities
D Gurwitz1, E Zika, M M Hopkins
1European Commission Joint Research Center, Institute for Prospective Technological Studies, Seville, Spain.
Public Health Genomics
|February 11, 2009
Summary
Pharmacogenetics/pharmacogenomics (PGx) applications in Europe are limited, with unmet expectations for clinical use. Overcoming barriers like data scarcity and lack of incentives requires policy support for industry-academia collaborations to advance PGx diagnostics.
Area of Science:
- Pharmacogenetics and Pharmacogenomics (PGx)
- Clinical Diagnostics
- Healthcare Policy
Background:
- High expectations for pharmacogenetics/pharmacogenomics (PGx) clinical applications in Europe remain largely unmet.
- Limited PGx applications have reached market and clinical practice, leaving healthcare and socio-economic impacts unclear.
- The European Commission's Joint Research Centre (JRC) reviewed the state of PGx and analyzed its use in preventing adverse drug reactions and improving efficacy.
Purpose of the Study:
- To review the current situation of PGx in Europe.
- To analyze the use of PGx diagnostics for preventing toxic drug reactions and improving drug efficacy.
- To identify barriers to clinical uptake and suggest policy improvements.
Main Methods:
- Review of the state-of-the-art in PGx in Europe.
- Analysis of PGx diagnostic test applications.
- Comparison of European experiences with the USA.
- Case-study illustration of barriers to clinical uptake.
Main Results:
- Significant barriers hinder the clinical translation of PGx research in Europe and globally.
- Scarcity of data on clinical validity, utility, and cost-effectiveness is a major issue.
- Lack of private sector incentives for developing PGx tests for existing drugs is a key barrier.
Conclusions:
- Policy interventions are crucial for advancing PGx clinical utility.
- Sustaining large-scale industry-academia collaborations is essential for developing and proving the utility of PGx diagnostics.
- Addressing data scarcity and incentivizing private sector investment are key to realizing PGx potential in healthcare.
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...